These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 17927212)

  • 1. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
    Luk KC; Hyde EG; Trojanowski JQ; Lee VM
    Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
    Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
    Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration.
    Li HT; Lin DH; Luo XY; Zhang F; Ji LN; Du HN; Song GQ; Hu J; Zhou JW; Hu HY
    FEBS J; 2005 Jul; 272(14):3661-72. PubMed ID: 16008565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
    Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
    Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
    El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
    FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation.
    Lu JH; Ardah MT; Durairajan SS; Liu LF; Xie LX; Fong WF; Hasan MY; Huang JD; El-Agnaf OM; Li M
    Chembiochem; 2011 Mar; 12(4):615-24. PubMed ID: 21271629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathology of synuclein aggregates.
    Duda JE; Lee VM; Trojanowski JQ
    J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures.
    Park SS; Lee D
    Eur J Neurosci; 2006 Jun; 23(11):2908-14. PubMed ID: 16819979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
    Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
    J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein.
    Mishizen-Eberz AJ; Norris EH; Giasson BI; Hodara R; Ischiropoulos H; Lee VM; Trojanowski JQ; Lynch DR
    Biochemistry; 2005 May; 44(21):7818-29. PubMed ID: 15909996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method.
    Tsukakoshi K; Abe K; Sode K; Ikebukuro K
    Anal Chem; 2012 Jul; 84(13):5542-7. PubMed ID: 22697251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of microtubule system increases alpha-synuclein aggregation and toxicity.
    Kim M; Jung W; Lee IH; Bhak G; Paik SR; Hahn JS
    Biochem Biophys Res Commun; 2008 Jan; 365(4):628-35. PubMed ID: 18022384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-time analysis of amyloid fibril formation of alpha-synuclein using a fibrillation-state-specific fluorescent probe of JC-1.
    Lee JH; Lee IH; Choe YJ; Kang S; Kim HY; Gai WP; Hahn JS; Paik SR
    Biochem J; 2009 Mar; 418(2):311-23. PubMed ID: 19007333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein.
    Smith DP; Tew DJ; Hill AF; Bottomley SP; Masters CL; Barnham KJ; Cappai R
    Biochemistry; 2008 Feb; 47(5):1425-34. PubMed ID: 18179253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of α-Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors.
    Jha NN; Kumar R; Panigrahi R; Navalkar A; Ghosh D; Sahay S; Mondal M; Kumar A; Maji SK
    ACS Chem Neurosci; 2017 Dec; 8(12):2722-2733. PubMed ID: 28872299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
    Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
    Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assembly of alpha-synuclein fibrils in nanoscale studied by peptide truncation and AFM.
    Zhang F; Lin XJ; Ji LN; Du HN; Tang L; He JH; Hu J; Hu HY
    Biochem Biophys Res Commun; 2008 Apr; 368(2):388-94. PubMed ID: 18230346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.